Toggle navigation
About
Abstract
Editorial Board
Subscription & Newsletter
Contact
Issues
This issue
22-4
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
22-4
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #42793
advertisement
Xu H
17
Showing records 1 to 17 |
Display all abstracts from
Xu H
99083
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study
Xu H
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 3001-3007
99354
Peripapillary Vascular Reactivity in Primary Open-Angle Glaucoma With High Myopia by Using Optical Coherence Tomography Angiography
Fan X
Frontiers in medicine
2022; 9: 850483
98529
Significance of the lncRNAs MALAT1 and ANRIL in occurrence and development of glaucoma
Huang G
Journal of Clinical Laboratory Analysis
2022; 36: e24215
99354
Peripapillary Vascular Reactivity in Primary Open-Angle Glaucoma With High Myopia by Using Optical Coherence Tomography Angiography
Xu H
Frontiers in medicine
2022; 9: 850483
98529
Significance of the lncRNAs MALAT1 and ANRIL in occurrence and development of glaucoma
Liang D
Journal of Clinical Laboratory Analysis
2022; 36: e24215
99083
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study
Thomas MT
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 3001-3007
99354
Peripapillary Vascular Reactivity in Primary Open-Angle Glaucoma With High Myopia by Using Optical Coherence Tomography Angiography
Zhai R
Frontiers in medicine
2022; 9: 850483
99083
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study
Lee D
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 3001-3007
98529
Significance of the lncRNAs MALAT1 and ANRIL in occurrence and development of glaucoma
Luo L; Lan C
Journal of Clinical Laboratory Analysis
2022; 36: e24215
99083
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study
Hirabayashi MT; Hirabayashi MT
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 3001-3007
99354
Peripapillary Vascular Reactivity in Primary Open-Angle Glaucoma With High Myopia by Using Optical Coherence Tomography Angiography
Sheng Q; Sun Y
Frontiers in medicine
2022; 9: 850483
98529
Significance of the lncRNAs MALAT1 and ANRIL in occurrence and development of glaucoma
Luo C
Journal of Clinical Laboratory Analysis
2022; 36: e24215
99083
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study
An JA
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 3001-3007
98529
Significance of the lncRNAs MALAT1 and ANRIL in occurrence and development of glaucoma
Xu H
Journal of Clinical Laboratory Analysis
2022; 36: e24215
99354
Peripapillary Vascular Reactivity in Primary Open-Angle Glaucoma With High Myopia by Using Optical Coherence Tomography Angiography
Shao T
Frontiers in medicine
2022; 9: 850483
98529
Significance of the lncRNAs MALAT1 and ANRIL in occurrence and development of glaucoma
Lai J
Journal of Clinical Laboratory Analysis
2022; 36: e24215
99354
Peripapillary Vascular Reactivity in Primary Open-Angle Glaucoma With High Myopia by Using Optical Coherence Tomography Angiography
Kong X
Frontiers in medicine
2022; 9: 850483
Issue
22-4
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept